<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
placeholder

Dr. Camidge on Toxicities of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

minute read

Written by OncLive on October 20, 2022

CU Cancer Center researcher Ross Camidge, MD, PhD, discusses toxicities observed with sunvozertinib (DZD9008) in EGFR Exon 20–Mutated non–small cell lung cancer (NSCLC).

Topics: Press Coverage

Comments

Related Stories